Current perspectives on targeting PIM kinases to overcome mechanisms of drug resistance and immune evasion in cancer.

@article{Malone2019CurrentPO,
  title={Current perspectives on targeting PIM kinases to overcome mechanisms of drug resistance and immune evasion in cancer.},
  author={Tom Malone and Lea Schӓfer and Natalie Simon and Susan Heavey and Sin{\'e}ad Cuffe and Stephen P. Finn and Gillian Moore and Kathy Gately},
  journal={Pharmacology \& therapeutics},
  year={2019},
  pages={
          107454
        }
}

Figures and Tables from this paper

Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer
TLDR
The preclinical inhibitor AUM302, used at a lower dose, elicited a comparable or superior functional outcome compared with combined AZD-1208 + BEZ235, which have been investigated in clinical trials, and could help to reduce treatment toxicity in future trials.
Co-Targeting PIM Kinase and PI3K/mTOR in NSCLC
TLDR
The data provides a rationale for co-targeting PIM kinase and PI3K-mTOR to improve therapeutic response in NSCLC and warrants further clinical investigation.
Macrocyclization as a Source of Desired Polypharmacology. Discovery of Triple PI3K/mTOR/PIM Inhibitors.
TLDR
The medicinal chemistry exploration and biological characterization of a series of thieno[3,2-d]pyrimidine MCXs led to the discovery of IBL-302, a potent, selective, and orally bioavailable triple PI3K/mTOR/PIM inhibitor.
Direct phosphorylation and stabilization of HIF-1α by PIM1 kinase drives angiogenesis in solid tumors
TLDR
A new signaling axis responsible for hypoxia-independent activation of HIF-1 is identified and the understanding of the tumorigenic role of PIM1 in solid tumors is expanded.
PIM protein kinases regulate the level of the long noncoding RNA H19 to control stem cell gene transcription and modulate tumor growth
TLDR
Results demonstrate that the PIM kinases control the level of lncRNA H19, which in turn modifies stem cell gene transcription regulating tumor growth.
Promise of the NLRP3 Inflammasome Inhibitors in In Vivo Disease Models
TLDR
Given the therapeutic promise of an NLRP3 inhibitor, the concerted escalated venture of the scientific sorority in the advancement of small molecules focusing on directNLRP3 inflammasome inhibition is quite predictable.
Metabolic regulation of T cell development
TLDR
Understanding the interplay between cellular metabolism and T cell developmental programs may offer an opportunity to selectively regulate T cell subset functions and to provide potential novel therapeutic approaches to modulate autoimmunity.
A systematic review on active sites and functions of PIM-1 protein.
TLDR
This intensive study can improve the understanding of PIM-1-regulated signaling pathways by facilitating the discovery of its potential phosphorylation substrates.
...
...

References

SHOWING 1-10 OF 195 REFERENCES
Activation of Pim Kinases Is Sufficient to Promote Resistance to MET Small-Molecule Inhibitors.
TLDR
It is reported that resistance to small-molecule inhibitors of MET can arise from increased expression of the prosurvival Pim protein kinases, and genetic or pharmacologic inhibition of Pim kinases was sufficient to restore sensitivity in vitro and in vivo.
Elevation of receptor tyrosine kinases by small molecule AKT inhibitors in prostate cancer is mediated by Pim-1.
TLDR
The results show that Pim-1 mediates resistance to AKT inhibition and suggest its targeting to improve the efficacy of AKT inhibitors in anticancer therapy.
Mechanisms Behind Resistance to PI3K Inhibitor Treatment Induced by the PIM Kinase
TLDR
PIM controls NAD(P)H production by increasing glucose flux through the pentose phosphate shunt decreasing ROS production, and thereby diminishing the cytotoxicity of PI3K-AKT inhibitors.
Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response
TLDR
The efficacy of antitumor T-cell therapy was markedly improved by inhibiting PIM kinases in tumor-bearing mice receiving ACT, and further enhanced by adding anti-PD1 antibody to this combination.
PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers
TLDR
Current knowledge about the role of PIM serine/threonine kinases for the pathogenesis and therapy of hematologic malignancies and solid cancers is summarized, structural principles and recent progress on small molecule PIM kinase inhibitors that are on their way into first clinical trials are highlighted.
Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents
TLDR
The unique ability of PIM inhibitors to concomitantly target HIF1 and selectively kill hypoxic tumor cells addresses two major components of tumor progression and therapeutic resistance.
Pim kinase inhibitors sensitize prostate cancer cells to apoptosis triggered by Bcl-2 family inhibitor ABT-737.
TLDR
The results suggest that this combination treatment could be developed as a potential therapy for human prostate cancer where overexpression of Pim kinases and antiapoptotic Bcl-2 family members drives tumor cell resistance to current anticancer therapies.
PIM kinase inhibitors: Structural and pharmacological perspectives.
PIM Kinases and Their Relevance to the PI3K/AKT/mTOR Pathway in the Regulation of Ovarian Cancer
TLDR
A connection between the PIM kinases and the PI3K/AKT/mTOR pathway and their parallel mechanism in the regulation of ovarian cancer is suggested.
Pim kinases in hematological malignancies: where are we now and where are we going?
TLDR
An overview of the biological activity of PIM-kinases, their role in hematologic malignancies and future therapeutic opportunities is provided.
...
...